$0.60
+0.05(9.45%)
Mkt Cap $2M
$0.37
$3.67
52-Week Range
At a Glance
AI-generatedEnsysce Biosciences faced a challenging fiscal year 2025, with escalating clinical development costs driving deeper operating losses and negative cash flow, while its future viability remains dependent on securing additional capital to fund its Phase 3 trial and ongoing operations.
Revenue breakdown: MPAR (79.3%), TAAPOUD (20.7%).
8-K
Ensysce Biosciences reported a net loss of $10.2 million for the full year 2025, driven by increased R&D spending for its lead drug candidates PF614 and PF614-MPAR, while highlighting clinical and regulatory progress including Phase 3 trial initiation and FDA engagement.$2M
Market Cap
$4M
Revenue
-$9M
Net Income
Employees7
Fundamentals
How The Business Makes Money
Revenue by Segment
MPAR79.3%($8M)
TAAPOUD20.7%($2M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001716947
ISINUS2936025046
CUSIP293602108
Phone858 263 4196
Address7946 Ivanhoe Avenue, La Jolla, CA, 92037, US
SEC EDGAR